Aficamten shows potential to be first FDA-approved treatment for nonobstructive HCM

Aficamten demonstrated significant efficacy in improving symptoms and exercise capacity in nonobstructive hypertrophic cardiomyopathy (HCM) patients, marking a potential first FDA-approved treatment for this condition. The phase III ACACIA-HCM trial showed clinically meaningful benefits, supporting regulatory approval efforts.

This Wire brief sits within Fusion42's coverage of Medtech.